The global antibody-drug conjugates (ADC) market was valued at USD 17.60 billion in 2025. It is estimated to reach USD 20.90 billion in 2026 and is projected to grow to USD 74.15 billion by 2036, at a CAGR of 13.5% during the 2026-2036 forecast period. This report provides a detailed assessment of the market, covering approved products and their sales performance, the clinical pipeline by phase and target, bispecific, dual-payload, and novel-payload conjugates, antibody, linker, payload, and conjugation technologies, M&A and licensing, regulation and reimbursement, manufacturing and supply, pricing, and competition.
ADCs pair a monoclonal antibody that recognizes an antigen on cancer or other diseased cells with a potent payload attached through a chemical linker, so that the drug is released mainly at the target while healthy tissue is spared. The study covers products by target, payload class (auristatins and maytansinoids, deruxtecan and other camptothecins, calicheamicin and PBD, and novel payloads), linker type, and format, across breast, urothelial, lung, gastric, and gynecologic cancers and blood cancers. Values reflect manufacturers' sales of approved medicines.
ADCs have become one of the main growth engines in oncology: Daiichi Sankyo and AstraZeneca reported combined Enhertu sales of USD 4.98 billion in 2025, up from USD 3.75 billion in 2024, after it became a routine choice for metastatic HER2-positive and HER2-low breast cancer and was extended to chemotherapy-naive HER2-low and HER2-ultralow patients. Pfizer reported Padcev revenue of USD 1.94 billion in 2025, up 22%, helped by first-line use with pembrolizumab in advanced urothelial cancer. According to the International Agency for Research on Cancer, about 20 million new cancer cases occurred worldwide in 2022, a figure projected to pass 35 million by 2050.
Toxicity is the main clinical restraint: Enhertu's label includes a boxed warning on interstitial lung disease, and ocular side effects contributed to the U.S. withdrawal of GSK's Blenrep in 2022 before its later return. Manufacturing is complex and costly, since highly potent payloads require containment and conjugation must control the drug-to-antibody ratio precisely, and only a few sites can produce at commercial scale. High prices limit access in many markets, as shown by NICE's 2024 decision not to recommend Enhertu for HER2-low metastatic breast cancer in England, and late-stage failures, such as the TROPION-Lung01 overall survival result for datopotamab deruxtecan, add risk. Further challenges include crowding around HER2 and TROP2, cross-resistance when ADCs with similar payloads are used in sequence, reliance on Chinese partners and contract manufacturers amid BIOSECURE Act scrutiny, and biosimilar entry as patents on Kadcyla and Adcetris expire.
Opportunities lie in bispecific and dual-payload ADCs, which aim to improve tumor selectivity and overcome resistance, as reflected in Bristol Myers Squibb's license of SystImmune's EGFR-HER3 bispecific izalontamab brengitecan, and in new payload classes such as immune-stimulating, degrader, and radiolabeled conjugates, as well as ADCs for autoimmune and other non-cancer diseases. Earlier lines of therapy and combinations with immunotherapy offer further upside, with trials testing Enhertu in first-line metastatic and early HER2-positive breast cancer. Key trends include the move from microtubule inhibitors toward topoisomerase I payloads, the rise of Chinese developers as a main source of licensed assets, consolidation through large acquisitions, and new high-potency manufacturing capacity at Lonza, WuXi XDC, Samsung Biologics, and others.
The target analysis spans HER2, TROP2, Nectin-4, hematologic targets (CD30, CD79b, CD22 & CD33, and BCMA), FRα, and emerging targets (B7-H3, HER3, c-Met, and others). HER2 is expected to hold the largest share in 2026, owing to Enhertu's scale and broad label across the HER2 spectrum of breast cancer and in other solid tumors, together with the long-established use of Kadcyla. TROP2 is expected to grow at the highest CAGR, as Datroway, Trodelvy, and Merck & Co.'s sacituzumab tirumotecan expand across breast and lung cancers, where TROP2 is widely expressed. Nectin-4 remains a major target in urothelial cancer through Padcev.
By payload, the report examines microtubule inhibitors (auristatins such as MMAE and MMAF, and maytansinoids such as DM1 and DM4), topoisomerase I inhibitors (deruxtecan and SN-38 and other camptothecins), DNA-damaging agents (calicheamicin and PBD), and novel payloads. Microtubule inhibitors are expected to account for the largest share in 2026, since several established ADCs, including Padcev, Adcetris, Polivy, and Kadcyla, use MMAE or maytansinoid payloads and have broad, mature labels. Topoisomerase I inhibitors are expected to grow at the highest CAGR, as these payloads allow higher drug loading, kill neighboring tumor cells with low target expression, and dominate the late-stage pipeline, led by Enhertu, Datroway, and Trodelvy.
By linker, the study covers cleavable and non-cleavable linkers. Cleavable linkers, which release the payload inside or near the tumor cell, are used in most recently approved ADCs, including deruxtecan-based products, and support the bystander effect that makes topoisomerase I payloads effective in tumors with uneven antigen levels. Non-cleavable linkers, used in Kadcyla, offer high stability in the bloodstream and remain important for established products, although their role is expected to shift as biosimilar versions enter price-sensitive markets.
Based on format, the market is segmented into monospecific, bispecific, and dual-payload ADCs. Monospecific ADCs are expected to account for the largest share in 2026, since currently marketed products bind a single target and carry well-established clinical evidence. Bispecific ADCs are expected to grow at the highest CAGR, as late-stage programs such as izalontamab brengitecan, which targets EGFR and HER3, aim to improve selectivity and internalization and to reach tumors that escape single-target therapy.
The indication analysis includes breast cancer (HER2-positive, HER2-low & HER2-ultralow, and triple-negative & HR+/HER2-), urothelial cancer, lung cancer, lymphoma, leukemia & multiple myeloma, gastric cancer, gynecologic cancers (ovarian, cervical, and endometrial), and others. Breast cancer is expected to account for the largest share in 2026, as Enhertu, Kadcyla, Trodelvy, and Datroway are used across most breast cancer subtypes and lines of therapy. Lung cancer is expected to grow at the highest CAGR, as ADCs aimed at HER2, TROP2, HER3, and c-Met win approvals or advance in trials for non-small cell lung cancer, a large patient population with few options after targeted therapy and immunotherapy.
By end user, the report covers hospitals, specialty cancer centers, and others. Hospitals are expected to account for the largest share in 2026, because ADCs are given by intravenous infusion and require monitoring for toxicities such as interstitial lung disease, neutropenia, and neuropathy. Specialty cancer centers are expected to grow at the highest CAGR, as complex ADC regimens, sequencing decisions, and clinical trials concentrate in dedicated oncology centers with experienced staff.
North America is expected to remain the largest regional market in 2026, as new ADCs usually launch first in the U.S., cancer drug spending is high, and many of the leading developers are based there. Daiichi Sankyo and AstraZeneca reported that Enhertu's in-market sales in the United States rose to USD 2.45 billion in 2025 from USD 1.86 billion in 2024, and Pfizer, Merck & Co., AbbVie, Bristol Myers Squibb, Gilead, and Johnson & Johnson all hold major ADC portfolios or pipelines. Europe holds a significant share, led by Germany, France, Italy, Spain, and the U.K., and is home to AstraZeneca, Roche, Genmab, BioNTech, and Lonza's bioconjugate production in Visp, although cost-effectiveness reviews slow uptake of some uses.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by China's emergence as a center of ADC discovery, wider reimbursement following Enhertu's addition to China's National Reimbursement Drug List in late 2024, and Japan's leadership through Daiichi Sankyo. Chinese companies, among them Kelun-Biotech, RemeGen, Hengrui, SystImmune, and Duality Biologics, are launching domestic ADCs and licensing assets abroad, South Korea is building ADC manufacturing and technology, and India has introduced biosimilar trastuzumab emtansine. In Latin America, Brazil and Mexico are the largest markets but budget limits restrain access, while in the Middle East & Africa, Saudi Arabia, the UAE, and Israel lead adoption.
Large drug makers with marketed ADCs and deep pipelines lead the market, competing with biotech specialists, Chinese developers that out-license their assets, linker-payload technology firms, and contract manufacturers. Rivals differ on clinical benefit and safety, choice of target and payload, how fast labels are extended, production capacity, pricing, and partnering. Enhertu is the leading product, and key strategies include label expansion into earlier lines, development of bispecific and novel-payload ADCs, acquisition and licensing of next-generation platforms, and investment in conjugation capacity, as seen in Pfizer's purchase of Seagen and Merck & Co.'s alliance with Daiichi Sankyo.
Key companies profiled in the report include AstraZeneca PLC (U.K.), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.), Astellas Pharma Inc. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), Bristol Myers Squibb Company (U.S.), Genmab A/S (Denmark), BioNTech SE (Germany), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), RemeGen Co., Ltd. (China), Lonza Group AG (Switzerland), and WuXi XDC Cayman Inc. (China).
ADCs pair a monoclonal antibody that recognizes an antigen on cancer or other diseased cells with a potent payload attached through a chemical linker, so that the drug is released mainly at the target while healthy tissue is spared. The study covers products by target, payload class (auristatins and maytansinoids, deruxtecan and other camptothecins, calicheamicin and PBD, and novel payloads), linker type, and format, across breast, urothelial, lung, gastric, and gynecologic cancers and blood cancers. Values reflect manufacturers' sales of approved medicines.
ADCs have become one of the main growth engines in oncology: Daiichi Sankyo and AstraZeneca reported combined Enhertu sales of USD 4.98 billion in 2025, up from USD 3.75 billion in 2024, after it became a routine choice for metastatic HER2-positive and HER2-low breast cancer and was extended to chemotherapy-naive HER2-low and HER2-ultralow patients. Pfizer reported Padcev revenue of USD 1.94 billion in 2025, up 22%, helped by first-line use with pembrolizumab in advanced urothelial cancer. According to the International Agency for Research on Cancer, about 20 million new cancer cases occurred worldwide in 2022, a figure projected to pass 35 million by 2050.
Market Dynamics
Growth is driven first by strong trial results and fast label expansion, as the DESTINY-Breast03, DESTINY-Breast04, and DESTINY-Breast06 trials widened Enhertu's use across breast cancer subtypes, and the EV-302 trial made Padcev plus pembrolizumab a first-line standard in urothelial cancer, with each new label adding patients and treatment time. Large pharmaceutical companies have made ADCs a strategic priority through deals such as Pfizer's 2023 purchase of Seagen, AbbVie's acquisition of ImmunoGen in 2024, Merck & Co.'s co-development agreement with Daiichi Sankyo for three DXd ADCs, and the 2024 acquisitions of Ambrx by Johnson & Johnson and ProfoundBio by Genmab. A growing and aging cancer population, with many patients relapsing after current treatment, adds long-term demand.Toxicity is the main clinical restraint: Enhertu's label includes a boxed warning on interstitial lung disease, and ocular side effects contributed to the U.S. withdrawal of GSK's Blenrep in 2022 before its later return. Manufacturing is complex and costly, since highly potent payloads require containment and conjugation must control the drug-to-antibody ratio precisely, and only a few sites can produce at commercial scale. High prices limit access in many markets, as shown by NICE's 2024 decision not to recommend Enhertu for HER2-low metastatic breast cancer in England, and late-stage failures, such as the TROPION-Lung01 overall survival result for datopotamab deruxtecan, add risk. Further challenges include crowding around HER2 and TROP2, cross-resistance when ADCs with similar payloads are used in sequence, reliance on Chinese partners and contract manufacturers amid BIOSECURE Act scrutiny, and biosimilar entry as patents on Kadcyla and Adcetris expire.
Opportunities lie in bispecific and dual-payload ADCs, which aim to improve tumor selectivity and overcome resistance, as reflected in Bristol Myers Squibb's license of SystImmune's EGFR-HER3 bispecific izalontamab brengitecan, and in new payload classes such as immune-stimulating, degrader, and radiolabeled conjugates, as well as ADCs for autoimmune and other non-cancer diseases. Earlier lines of therapy and combinations with immunotherapy offer further upside, with trials testing Enhertu in first-line metastatic and early HER2-positive breast cancer. Key trends include the move from microtubule inhibitors toward topoisomerase I payloads, the rise of Chinese developers as a main source of licensed assets, consolidation through large acquisitions, and new high-potency manufacturing capacity at Lonza, WuXi XDC, Samsung Biologics, and others.
Segment Analysis
The report analyzes the global ADC market by target, payload, linker, format, indication, end user, and geography, helping stakeholders understand where sales are generated today and where next-generation products will add value.The target analysis spans HER2, TROP2, Nectin-4, hematologic targets (CD30, CD79b, CD22 & CD33, and BCMA), FRα, and emerging targets (B7-H3, HER3, c-Met, and others). HER2 is expected to hold the largest share in 2026, owing to Enhertu's scale and broad label across the HER2 spectrum of breast cancer and in other solid tumors, together with the long-established use of Kadcyla. TROP2 is expected to grow at the highest CAGR, as Datroway, Trodelvy, and Merck & Co.'s sacituzumab tirumotecan expand across breast and lung cancers, where TROP2 is widely expressed. Nectin-4 remains a major target in urothelial cancer through Padcev.
By payload, the report examines microtubule inhibitors (auristatins such as MMAE and MMAF, and maytansinoids such as DM1 and DM4), topoisomerase I inhibitors (deruxtecan and SN-38 and other camptothecins), DNA-damaging agents (calicheamicin and PBD), and novel payloads. Microtubule inhibitors are expected to account for the largest share in 2026, since several established ADCs, including Padcev, Adcetris, Polivy, and Kadcyla, use MMAE or maytansinoid payloads and have broad, mature labels. Topoisomerase I inhibitors are expected to grow at the highest CAGR, as these payloads allow higher drug loading, kill neighboring tumor cells with low target expression, and dominate the late-stage pipeline, led by Enhertu, Datroway, and Trodelvy.
By linker, the study covers cleavable and non-cleavable linkers. Cleavable linkers, which release the payload inside or near the tumor cell, are used in most recently approved ADCs, including deruxtecan-based products, and support the bystander effect that makes topoisomerase I payloads effective in tumors with uneven antigen levels. Non-cleavable linkers, used in Kadcyla, offer high stability in the bloodstream and remain important for established products, although their role is expected to shift as biosimilar versions enter price-sensitive markets.
Based on format, the market is segmented into monospecific, bispecific, and dual-payload ADCs. Monospecific ADCs are expected to account for the largest share in 2026, since currently marketed products bind a single target and carry well-established clinical evidence. Bispecific ADCs are expected to grow at the highest CAGR, as late-stage programs such as izalontamab brengitecan, which targets EGFR and HER3, aim to improve selectivity and internalization and to reach tumors that escape single-target therapy.
The indication analysis includes breast cancer (HER2-positive, HER2-low & HER2-ultralow, and triple-negative & HR+/HER2-), urothelial cancer, lung cancer, lymphoma, leukemia & multiple myeloma, gastric cancer, gynecologic cancers (ovarian, cervical, and endometrial), and others. Breast cancer is expected to account for the largest share in 2026, as Enhertu, Kadcyla, Trodelvy, and Datroway are used across most breast cancer subtypes and lines of therapy. Lung cancer is expected to grow at the highest CAGR, as ADCs aimed at HER2, TROP2, HER3, and c-Met win approvals or advance in trials for non-small cell lung cancer, a large patient population with few options after targeted therapy and immunotherapy.
By end user, the report covers hospitals, specialty cancer centers, and others. Hospitals are expected to account for the largest share in 2026, because ADCs are given by intravenous infusion and require monitoring for toxicities such as interstitial lung disease, neutropenia, and neuropathy. Specialty cancer centers are expected to grow at the highest CAGR, as complex ADC regimens, sequencing decisions, and clinical trials concentrate in dedicated oncology centers with experienced staff.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 20 countries and five rest-of-region groups. The regional analysis considers approval timing, pricing and reimbursement, cancer incidence, treatment infrastructure, and local development and manufacturing activity.North America is expected to remain the largest regional market in 2026, as new ADCs usually launch first in the U.S., cancer drug spending is high, and many of the leading developers are based there. Daiichi Sankyo and AstraZeneca reported that Enhertu's in-market sales in the United States rose to USD 2.45 billion in 2025 from USD 1.86 billion in 2024, and Pfizer, Merck & Co., AbbVie, Bristol Myers Squibb, Gilead, and Johnson & Johnson all hold major ADC portfolios or pipelines. Europe holds a significant share, led by Germany, France, Italy, Spain, and the U.K., and is home to AstraZeneca, Roche, Genmab, BioNTech, and Lonza's bioconjugate production in Visp, although cost-effectiveness reviews slow uptake of some uses.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by China's emergence as a center of ADC discovery, wider reimbursement following Enhertu's addition to China's National Reimbursement Drug List in late 2024, and Japan's leadership through Daiichi Sankyo. Chinese companies, among them Kelun-Biotech, RemeGen, Hengrui, SystImmune, and Duality Biologics, are launching domestic ADCs and licensing assets abroad, South Korea is building ADC manufacturing and technology, and India has introduced biosimilar trastuzumab emtansine. In Latin America, Brazil and Mexico are the largest markets but budget limits restrain access, while in the Middle East & Africa, Saudi Arabia, the UAE, and Israel lead adoption.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, the competitive dashboard, and 2025 market share/rank analysis, with company profiles grouped into marketed ADC leaders, pipeline and partnering leaders, Chinese ADC developers, and ADC manufacturing, each covering business overview, financials, product portfolio, strategic developments, and SWOT analysis.Large drug makers with marketed ADCs and deep pipelines lead the market, competing with biotech specialists, Chinese developers that out-license their assets, linker-payload technology firms, and contract manufacturers. Rivals differ on clinical benefit and safety, choice of target and payload, how fast labels are extended, production capacity, pricing, and partnering. Enhertu is the leading product, and key strategies include label expansion into earlier lines, development of bispecific and novel-payload ADCs, acquisition and licensing of next-generation platforms, and investment in conjugation capacity, as seen in Pfizer's purchase of Seagen and Merck & Co.'s alliance with Daiichi Sankyo.
Key companies profiled in the report include AstraZeneca PLC (U.K.), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.), Astellas Pharma Inc. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), Bristol Myers Squibb Company (U.S.), Genmab A/S (Denmark), BioNTech SE (Germany), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), RemeGen Co., Ltd. (China), Lonza Group AG (Switzerland), and WuXi XDC Cayman Inc. (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global antibody-drug conjugates market through 2036.
- Explains how label expansion, earlier-line use, and immunotherapy combinations are enlarging the treated population.
- Assesses the impact of toxicity, manufacturing complexity, pricing and reimbursement, and clinical setbacks on market growth.
- Identifies high-growth opportunities across target, payload, linker, format, indication, end user, and region.
- Tracks next-generation technologies such as bispecific, dual-payload, immune-stimulating, and degrader conjugates.
- Benchmarks leading drug developers, Chinese innovators, and contract manufacturers on portfolios, pipelines, deals, and capacity.
- Supports portfolio strategy, business development, licensing, manufacturing investment, and market access decisions.
Key Questions Answered
- How large is the global antibody-drug conjugates market today, and how will it grow through 2036?
- How are Enhertu, Padcev, and other leading ADCs expanding into earlier lines and new tumor types?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will the shift from microtubule inhibitors to topoisomerase I payloads change the market mix?
- Which target, payload, linker, format, indication, and end user segments will grow the fastest?
- How quickly will bispecific, dual-payload, and novel-payload ADCs reach the market?
- Which regions and countries offer the most attractive opportunities, and how is China's role changing?
- How are acquisitions, licensing deals, and manufacturing investments reshaping competition?
- Who are the leading companies in the market, and how do they compare?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Antibody-Drug Conjugates Market, by Target
6. Antibody-Drug Conjugates Market, by Payload
7. Antibody-Drug Conjugates Market, by Linker
8. Antibody-Drug Conjugates Market, by Format
9. Antibody-Drug Conjugates Market, by Indication
10. Antibody-Drug Conjugates Market, by End User
11. Antibody-Drug Conjugates Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Pfizer Inc.
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- GSK plc
- Merck & Co., Inc.
- Johnson & Johnson
- Bristol Myers Squibb Company
- Genmab A/S
- BioNTech SE
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- RemeGen Co., Ltd.
- Lonza Group AG
- WuXi XDC Cayman Inc.
